Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

por Powles, T, Shamash, J, Berney, D, Oliver, R T D
Publicado 2003

A case of insulin and ACTH co-secretion by a neuroendocrine tumour

por Solomou, S, Khan, R, Propper, D, Berney, D, Druce, M
Publicado 2014

DNA topoisomerase I and II expression in drug resistantgerm cell tumours

por Berney, D M, Shamash, J, Gaffney, J, Jordan, S, Oliver, R T D
Publicado 2002

Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided?

por Berney, D M, Shamash, J, Hendry, W F, Arora, A, Jordan, S, Oliver, R T
Publicado 2001

Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb

por Hitchings, A W, Kumar, M, Jordan, S, Nargund, V, Martin, J, Berney, D M
Publicado 2004

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort

por Fisher, G, Yang, Z H, Kudahetti, S, Møller, H, Scardino, P, Cuzick, J, Berney, D M
Publicado 2013

The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas

por Tufton, N, Hearnden, R J, Berney, D M, Drake, W M, Parvanta, L, Chapple, J P, Akker, S A
Publicado 2022

Pure aldosterone-secreting adrenocortical carcinoma in a patient with refractory primary hyperaldosteronism

por Hussain, S, Panteliou, E, Berney, D M, Carpenter, R, Matson, M, Sahdev, A, Bell, M, O'Sullivan, E, Drake, W M
Publicado 2015

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours

por Shamash, J, Powles, T, Ansell, W, Berney, D, Stebbing, J, Mutsvangwa, K, Wilson, P, Asterling, S, Liu, S, Wyatt, P, Joel, S P, Oliver, R T D
Publicado 2007

Long-term outcome among men with conservatively treated localised prostate cancer

por Cuzick, J, Fisher, G, Kattan, M W, Berney, D, Oliver, T, Foster, C S, Møller, H, Reuter, V, Fearn, P, Eastham, J, Scardino, P
Publicado 2006

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma

por Bharwani, N, Miquel, M E, Powles, T, Dilks, P, Shawyer, A, Sahdev, A, Wilson, P D, Chowdhury, S, Berney, D M, Rockall, A G
Publicado 2014

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice

por Newton, C., Murali, K., Ahmad, A., Hockings, H., Graham, R., Liberale, V., Sarker, S.-J., Ledermann, J., Berney, D.M., Shamash, J., Banerjee, S., Stoneham, S., Lockley, M.
Publicado 2019

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

por Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.
Publicado 2011

Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer

por Vasiljević, N, Ahmad, A S, Beesley, C, Thorat, M A, Fisher, G, Berney, D M, Møller, H, Yu, Y, Lu, Y-J, Cuzick, J, Foster, C S, Lorincz, A T
Publicado 2013

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer

por Ahmad, I, Singh, L B, Yang, Z H, Kalna, G, Fleming, J, Fisher, G, Cooper, C, Cuzick, J, Berney, D M, Møller, H, Scardino, P, Leung, H Y
Publicado 2013

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study

por Berney, D M, Gopalan, A, Kudahetti, S, Fisher, G, Ambroisine, L, Foster, C S, Reuter, V, Eastham, J, Moller, H, Kattan, M W, Gerald, W, Cooper, C, Scardino, P, Cuzick, J
Publicado 2009

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

por Cuzick, J, Berney, D M, Fisher, G, Mesher, D, Møller, H, Reid, J E, Perry, M, Park, J, Younus, A, Gutin, A, Foster, C S, Scardino, P, Lanchbury, J S, Stone, S
Publicado 2012

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement

por Foster, C S, Dodson, A R, Ambroisine, L, Fisher, G, Møller, H, Clark, J, Attard, G, De-Bono, J, Scardino, P, Reuter, V E, Cooper, C S, Berney, D M, Cuzick, J
Publicado 2009

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer

por Cuzick, J, Yang, Z H, Fisher, G, Tikishvili, E, Stone, S, Lanchbury, J S, Camacho, N, Merson, S, Brewer, D, Cooper, C S, Clark, J, Berney, D M, Møller, H, Scardino, P, Sangale, Z
Publicado 2013

Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort

por Cuzick, J, Stone, S, Fisher, G, Yang, Z H, North, B V, Berney, D M, Beltran, L, Greenberg, D, Møller, H, Reid, J E, Gutin, A, Lanchbury, J S, Brawer, M, Scardino, P
Publicado 2015